We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UCB to File Two More Cimzia Arthritis Indications This Year, Tables RA Drug
UCB to File Two More Cimzia Arthritis Indications This Year, Tables RA Drug
November 2, 2012
UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis (AxSpA), including ankylosing spondylitis (AS), to the FDA and EU by the end of the year.